RenovoRx (RNXT) Expected to Announce Earnings on Thursday

RenovoRx (NASDAQ:RNXT) is expected to post its Q1 2025 quarterly earnings results after the market closes on Thursday, May 15th. Analysts expect RenovoRx to post earnings of ($0.10) per share and revenue of $0.23 million for the quarter.

RenovoRx (NASDAQ:RNXT) last released its earnings results on Monday, March 31st. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.17 million. On average, analysts expect RenovoRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RenovoRx Stock Performance

NASDAQ:RNXT opened at $1.03 on Wednesday. The stock has a 50-day simple moving average of $0.96 and a two-hundred day simple moving average of $1.13. The firm has a market capitalization of $37.65 million, a PE ratio of -1.81 and a beta of 1.12. RenovoRx has a 52-week low of $0.75 and a 52-week high of $1.69.

Analysts Set New Price Targets

A number of equities research analysts have commented on RNXT shares. Ascendiant Capital Markets raised their target price on shares of RenovoRx from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, April 28th. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of RenovoRx in a research note on Friday, April 4th.

About RenovoRx

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.